20.11.2024 07:30:01 CET | Thor Medical ASA | Ikke-informasjonspliktige
pressemeldinger

Thor Medical, a leading emerging supplier of alpha-emitters for next-generation
precision cancer treatment, is pleased to invite investors and other interested
parties to a capital markets update on Monday, 25 November, 2024.

This is a reminder to enable you to save the date in your calendar. Please reach
out to request 1-on-1 meetings with management, see details below.

Thor Medical's CEO Jasper Kurth and CFO Brede Ellingsæter will present an
updated investor presentation and will be accompanied by Emanuele Ostuni, CEO of
ARTBIO.

Keynote speaker for Thor Medical's Capital Markets Update is Professor Jane
Sosabowski, BSc (Hons), MSc, PhD from the Centre for Cancer Biomarkers and
Biotherapeutics, Barts Cancer Institute, Queen Mary University of London.
Professor Sosabowski will provide a perspective on treatment with upcoming
targeted alpha therapies using isotopes that Thor Medical produces.

As announced on 29 October, Thor Medical has signed a 5-year master supply
agreement for Thorium-228 with ARTBIO. The agreement marks a significant step
towards a positive investment decision for Thor Medical's planned commercial
production plant, targeted in Q1 2025.

The event will be held at Carnegie's premises in Stockholm, Sweden and a live
webcast will be available for those who cannot attend in person.

Location: Regeringsgatan 56, 111 56 Stockholm

Date & Time: 25 November 2024, 13:00-15:00 CET

Registration for physical or digital attendance to the capital markets update
can be done through the following link:

https://tinyurl.com/2jx2hxzp

It will be possible to ask questions both from the audience and via webcast
during the presentations.

For inquiries regarding one-on-one meetings or other event-related questions,
kindly send an email to ellen.mioen@carnegie.se

KONTAKTER

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
   brede.ellingseter@thormedical.com 

OM THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

VEDLEGG

Last ned som PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18328946/5312/Last%20ned%20som%20
PDF.pdf